Voskuil Michiel D, Mittal Shruti, Sharples Edward J, Vaidya Anil, Gilbert James, Friend Peter J, Ploeg Rutger J
Oxford Transplant Centre, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Clin Transplant. 2014 Sep;28(9):1047-53. doi: 10.1111/ctr.12416. Epub 2014 Jul 22.
Graft survival after pancreas transplantation alone (PTA) is significantly poorer than graft survival after simultaneous pancreas kidney (SPK) and is particularly affected by difficulty in monitoring rejection. Exocrine bladder drainage allows assessment of pancreas graft function as urinary amylase (UA). However, standards for UA collection and interpretation are not well defined. In this study, 21 bladder-drained PTA recipients were monitored with daily values for UA and urine creatinine (Creat) concentration from post-transplant 10-mL samples and 24-h collections. Clinical events were documented and correlated to UA measurements. UA values were found to increase post-transplant until day 15, and large interpatient variability was noted (median 12 676 IU/L, range 668-60 369 IU/L). A strong correlation was found total 24-h UA production and spot UA/Creat ratio (r = 0.80, p < 0.001). UA/Creat ratio showed less variation during episodes of impaired renal function; therefore, urinary amylase baseline was defined as the median UA/Creat ratio after day 15. A > 25% decrease of UA predicted 9/13 (69%) events. We conclude that individual baselines should be set once the values have stabilized after 15 d post-transplant and that spot UA/Creat measures are reliable, patient friendly and indicate potential events after PTA.
单纯胰腺移植(PTA)后的移植物存活率显著低于同期胰肾联合移植(SPK),且特别容易受到排斥反应监测困难的影响。外分泌膀胱引流可通过尿淀粉酶(UA)评估胰腺移植物功能。然而,UA收集和解读的标准尚未明确界定。在本研究中,对21例采用膀胱引流的PTA受者进行监测,记录移植后10毫升样本和24小时尿液收集的每日UA和尿肌酐(Creat)浓度值。记录临床事件并与UA测量值相关联。发现UA值在移植后至第15天升高,且患者间存在较大差异(中位数为12676 IU/L,范围为668 - 60369 IU/L)。发现24小时总UA产生量与即时UA/Creat比值之间存在强相关性(r = 0.80,p < 0.001)。在肾功能受损期间,UA/Creat比值变化较小;因此,将尿淀粉酶基线定义为移植后第15天之后的UA/Creat比值中位数。UA下降>25%可预测13例事件中的9例(69%)。我们得出结论,应在移植后15天数值稳定后设定个体基线,即时UA/Creat测量可靠、对患者友好,并可提示PTA后的潜在事件。